Tofaxen (Tofacitinib) Tablets
Tofaxen 5 mg (Tofacitinib) is an oral Janus kinase (JAK) inhibitor used to treat chronic inflammatory conditions.
Manufacturer: Everest Pharmaceuticals. Each pack contains 60 tablets. It works by interfering with the JAK-STAT signaling pathway, which plays a central role in the immune system's inflammatory response, thereby reducing symptoms like pain and swelling.
Key Feature:
Tofaxen offers a targeted approach in a convenient oral tablet form, often prescribed when patients do not respond well to methotrexate or other biological DMARDs.
Indicated for the treatment of adult patients with:
- 🔹 Rheumatoid Arthritis (RA): Moderate to severe active RA.
- 🔹 Psoriatic Arthritis: Active psoriatic arthritis (usually used in combination with non-biologic DMARDs).
- 🔹 Ulcerative Colitis: Moderately to severely active disease (induction and maintenance).
- 🔹 Ankylosing Spondylitis: Active disease requiring systemic therapy.
Packaging: 5 mg film-coated tablets.
⚠️ ADMINISTRATION PROTOCOL:
- Standard Dose: 5 mg taken twice daily.
- For Ulcerative Colitis: Initial dose may be 10 mg twice daily for at least 8 weeks, followed by a maintenance dose of 5 mg twice daily, as prescribed by a physician.
- Administration: Swallow whole with water. Can be taken with or without food.
- Adjustment: Dosage may need adjustment in patients with moderate renal or hepatic impairment.
- Active serious infections (e.g., tuberculosis, sepsis).
- Severe hepatic impairment.
- Pregnancy and breastfeeding (potential risk to the fetus).
- Known hypersensitivity to Tofacitinib.
Common and serious adverse reactions include:
- 🦠 Infections: Upper respiratory tract infections, nasopharyngitis, herpes zoster (shingles).
- 🩸 Labs: Increased cholesterol levels (dyslipidemia), headache.
- 🌀 Physical: Diarrhea, hypertension, nausea.
- ⚠️ Warning: Increases the risk of serious infections and thrombosis. Regular blood monitoring is required.
Similar products
What Customers Say
No reviews yet
Your review can be the first!